Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 24Terminated 4Withdrawn 3Recruiting 3Active not recruiting 2No longer available 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 2Sarcoma 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 71Precursor Cell Lymphoblastic Leukemia-Lymphoma 21Myelodysplastic Syndromes 14Leukemia, Biphenotypic, Acute 14Recurrence 13Leukemia 12Burkitt Lymphoma 12Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 7Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 7Leukemia, Myelomonocytic, Chronic 6Lymphoma, Mantle-Cell 5Neoplasm, Residual 4Myeloproliferative Disorders 4Lymphoma, Large B-Cell, Diffuse 4Hodgkin Disease 4Hematologic Neoplasms 4Sarcoma, Myeloid 3Lymphoma, T-Cell 3Lymphoma 3Blast Crisis 3Lymphoma, Non-Hodgkin 2Leukemia, Myelomonocytic, Juvenile 2Leukemia, Myeloid 2Down Syndrome 2Blastic Plasmacytoid Dendritic Cell Neoplasm 2Anemia, Refractory, with Excess of Blasts 2Targeted Therapy 1Pyloric Stenosis, Hypertrophic 1Neurofibromatosis 1 1Neoplasms by Histologic Type 1

Interventions

Cytarabine 3ponatinib 2blinatumomab 2Idarubicin 2Cladribine 2venetoclax 1nilotinib 1midostaurin 1merphos 1gilteritinib 1fludarabine 1bosutinib 1asciminib 1Succimer 1Specimen Handling 1Razoxane 1Positron-Emission Tomography 1Pentetic Acid 1N,N-dicyclohexyl-isoborneol-10-sulfonamide 1Methotrexate 1Magnetic Resonance Spectroscopy 1Imatinib Mesylate 1Geritol 1Gemtuzumab 1Edetic Acid 1Dexrazoxane 1Dasatinib 1Cyclophosphamide 1Blood Component Removal 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Blast Crisis × Cytarabine × Clear all
NCT03589729 2026-05-22

Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers

M.D. Anderson Cancer Center

Phase 2 Recruiting
100 enrolled
MyeloidOther hematologic neoplasmSarcoma

Blast Crisis, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Sarcoma, Myeloid

NCT02115295 2026-05-20

Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia

M.D. Anderson Cancer Center

Phase 2 Recruiting
508 enrolled
MyeloidOther hematologic neoplasm

Blast Crisis, Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute

NCT03263572 2026-05-20

Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia

M.D. Anderson Cancer Center

Phase 2 Recruiting
90 enrolled
LymphoidOther hematologic neoplasm

Blast Crisis, Leukemia, Myeloid, Accelerated Phase, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡